Standard of Care sensibility: Anti-PD1 = partial / Anti-PDL1 = no (12.5mg/kg).
Mammary Gland
Syngeneic breast cancer tumour model – 4T1
4T1 cells
Mouse 4T1 cells were isolated from the spontaneous tumour in the mammary gland of a BALB/C mouse with the animal equivalent of a stage IV breast cancer.
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of BALB/C mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing 4T1 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (view pdf)
Tumour growth curve of the 4T1 cells as subcutaneous tumours, Mean ± SEM
Antineo can also implant this model orthotopically.
Drug Response – Doxorubicin
Figure 2: (view pdf)
Effect of Doxorubicin at 1mg/kg or 2mg/kg on 4T1 tumour growth, Mean ± SEM
Drug Response – Anti-PD1
Figure 3: (view pdf)
Partial response of Anti-PD1 at 12.5mg/kg on 4T1 tumour growth, Mean ± SEM
Drug Response – Anti-PDL1
Anti-PDL1 12.5 mg/kg no response and toxic.
Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.
Download the 4T1 – 2025 PDF File